vorinostat and Viremia
vorinostat has been researched along with Viremia in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Viremia: The presence of viruses in the blood.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0." | 3.11 | Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. ( Aga, E; Archin, N; Bosch, RJ; Chomont, N; Connick, E; Coxen, K; Deeks, S; Dobrowolski, C; Ehui, L; Gandhi, M; Gandhi, RT; Giguel, F; Godfrey, C; Hosey, L; Howell, BJ; Karn, J; Kuritzkes, DR; Ma, Q; Morse, GD; Scully, EP; Sieg, SF; Squires, KE; Starr, K; Tsibris, A; Wu, G, 2022) |
Research
Studies (6)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
Authors
Authors | Studies |
---|---|
Gay, CL | 1 |
James, KS | 1 |
Tuyishime, M | 1 |
Falcinelli, SD | 1 |
Joseph, SB | 1 |
Moeser, MJ | 1 |
Allard, B | 1 |
Kirchherr, JL | 1 |
Clohosey, M | 1 |
Raines, SLM | 1 |
Montefiori, DC | 1 |
Shen, X | 1 |
Gorelick, RJ | 1 |
Gama, L | 1 |
McDermott, AB | 1 |
Koup, RA | 1 |
Mascola, JR | 1 |
Floris-Moore, M | 1 |
Kuruc, JD | 2 |
Ferrari, G | 1 |
Eron, JJ | 2 |
Archin, NM | 2 |
Margolis, DM | 2 |
Scully, EP | 1 |
Aga, E | 1 |
Tsibris, A | 1 |
Archin, N | 1 |
Starr, K | 1 |
Ma, Q | 1 |
Morse, GD | 1 |
Squires, KE | 1 |
Howell, BJ | 1 |
Wu, G | 1 |
Hosey, L | 1 |
Sieg, SF | 1 |
Ehui, L | 1 |
Giguel, F | 1 |
Coxen, K | 1 |
Dobrowolski, C | 1 |
Gandhi, M | 1 |
Deeks, S | 1 |
Chomont, N | 1 |
Connick, E | 1 |
Godfrey, C | 1 |
Karn, J | 1 |
Kuritzkes, DR | 1 |
Bosch, RJ | 3 |
Gandhi, RT | 1 |
Cillo, AR | 1 |
Sobolewski, MD | 1 |
Fyne, E | 1 |
Piatak, M | 2 |
Coffin, JM | 2 |
Mellors, JW | 1 |
Ling, B | 1 |
Rogers, L | 1 |
Johnson, AM | 1 |
Russell-Lodrigue, K | 1 |
Hazuda, DJ | 2 |
Lifson, JD | 1 |
Veazey, RS | 1 |
Barton, K | 1 |
Hiener, B | 1 |
Winckelmann, A | 1 |
Rasmussen, TA | 1 |
Shao, W | 1 |
Byth, K | 1 |
Lanfear, R | 1 |
Solomon, A | 1 |
McMahon, J | 1 |
Harrington, S | 1 |
Buzon, M | 1 |
Lichterfeld, M | 1 |
Denton, PW | 1 |
Olesen, R | 1 |
Østergaard, L | 1 |
Tolstrup, M | 1 |
Lewin, SR | 1 |
Søgaard, OS | 1 |
Palmer, S | 1 |
Liberty, AL | 1 |
Kashuba, AD | 1 |
Choudhary, SK | 1 |
Crooks, AM | 1 |
Parker, DC | 1 |
Anderson, EM | 1 |
Kearney, MF | 1 |
Strain, MC | 1 |
Richman, DD | 1 |
Hudgens, MG | 1 |
Clinical Trials (11)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)[NCT03803605] | Phase 1 | 15 participants (Actual) | Interventional | 2019-02-12 | Completed | ||
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors[NCT03382834] | Phase 2 | 31 participants (Actual) | Interventional | 2018-04-26 | Active, not recruiting | ||
Investigation of the Impact of Inducible, Replication-competent Latent HIV-1 as an Impediment to HIV/AIDS Cure in the Context of Sustained Viral Suppression[NCT04938518] | 222 participants (Anticipated) | Observational [Patient Registry] | 2019-05-01 | Recruiting | |||
Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV[NCT03692611] | 280 participants (Actual) | Interventional | 2019-08-14 | Active, not recruiting | |||
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection[NCT02042248] | Phase 1 | 6 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection[NCT02071095] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167] | Phase 1 | 6 participants (Actual) | Interventional | 2015-04-07 | Completed | ||
A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy[NCT01319383] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
Research In Viral Eradication of HIV Reservoirs[NCT02336074] | Phase 2 | 60 participants (Actual) | Interventional | 2015-11-27 | Completed | ||
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol. (NCT03803605)
Timeframe: First day of study treatment through end of study, a total of approximately 36 weeks
Intervention | percentage of participants (Number) |
---|---|
VRC07-523LS + Vorinostat (VOR) | 0 |
Change From Baseline in Cell-associated HIV-1 RNA in CD4+ T Cells
Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Cell-associated HIV-1 RNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38
Intervention | log10 copies/million CD4 cells (Mean) |
---|---|
Arm A: Tamoxifen + Vorinostat | 0.06 |
Arm B: Vorinostat Alone | 0.17 |
Change From Baseline in Total HIV-1 DNA Levels in CD4+ T Cells
Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Total HIV-1 DNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38
Intervention | log10 copies/million CD4 cells (Mean) |
---|---|
Arm A: Tamoxifen + Vorinostat | 0 |
Arm B: Vorinostat Alone | -0.04 |
Proportion of Participants With New Grade 3 or Greater Adverse Events
Proportion of participants with new Grade 3 or greater adverse events that are considered definitely, probably, or possibly related to study treatment (as judged by the core protocol team). The DAIDS AE Grading Table (corrected Version 2.1, July 2017) was used. (NCT03382834)
Timeframe: Measured from study entry through Day 65
Intervention | proportion of participants (Number) |
---|---|
Arm A: Tamoxifen + Vorinostat | 0 |
Arm B: Vorinostat Alone | 0 |
Number of Participants With HIV-1 RNA Levels (Measured by Single Copy Assay) Greater or Equal to the Lower Limit of Quantification
Number of participants with HIV-1 RNA levels measured by single copy assay (SCA) greater or equal to the lower limit of quantification (LOQ). The lower limit of quantification for this study was 0.47 copies/mL. (NCT03382834)
Timeframe: Pre-entry, entry, Day 28, Day 35, Day 38 (5 hours post vorinostat), Day 45, Day 65
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Pre-entry SCA >= LOQ | Entry SCA >=LOQ | Day 28 SCA >=LOQ | Day 35 SCA >=LOQ | Day 38 SCA >=LOQ | Day 45 SCA >=LOQ | Day 65 SCA >=LOQ | |
Arm A: Tamoxifen + Vorinostat | 10 | 9 | 11 | 11 | 7 | 9 | 10 |
Arm B: Vorinostat Alone | 6 | 3 | 4 | 5 | 5 | 4 | 5 |
CD8 CD38 (Mean of Fluorescence)
the CD38-activation marker on CD8 T-cells (CD8/CD38). (NCT02071095)
Timeframe: Day 8
Intervention | mean fluorescent intensity (MFI) (Mean) |
---|---|
Arm A: Poly-ICLC | 8.69 |
Arm B: Normal Saline | 2.35 |
NK Cell Number
Natural killer cells or NK cells are part of the innate immune defense against infection and cancer. (NCT02071095)
Timeframe: at 48 weeks
Intervention | cells/µL (Mean) |
---|---|
Arm A: Poly-ICLC | 20.68 |
Arm B: Normal Saline | 19.41 |
Number Participants With Adverse Events
Safety measured by number of participants with adverse events. (NCT02071095)
Timeframe: Up to 48 weeks
Intervention | Participants (Count of Participants) |
---|---|
Arm A: Poly-ICLC | 11 |
Arm B: Normal Saline | 3 |
Percent Change in CD4+ Tcell-associated HIV-1 RNA as Compared to Baseline
CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline. (NCT02071095)
Timeframe: Baseline, Day 2, Day 4, Day 8, Day 28
Intervention | percent change (Mean) | |||
---|---|---|---|---|
Day 2 | Day 4 | Day 8 | Day 28 | |
Arm A: Poly-ICLC | 102.8 | 134.8 | 161.0 | 199.6 |
Arm B: Normal Saline | 186.3 | 254.7 | 66.33 | 126.7 |
Plasma Interferon-gamma-inducible Protein-10 (IP-10) Level
One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8-500 pg/ml. (NCT02071095)
Timeframe: Day 2 and Day 4
Intervention | pg/ml (Mean) | |
---|---|---|
Day 2 | Day 4 | |
Arm A: Poly-ICLC | 381.43 | 450.51 |
Arm B: Normal Saline | 100.65 | 139.39 |
Number of Participants Developing Cancer Within 5 Years Following >/= 8 Vorinostat Dose Exposures
Development of a new cancer within the 5 years of taking their last dose of VOR 400 mg PO.All participants receiving one or more doses of VOR 400 mg PO in any and all Arms of the study. Pre-specified to be reported as one group. (NCT01319383)
Timeframe: From last dose Vorinostat to 5 years afterwards
Intervention | Participants (Count of Participants) |
---|---|
1/Single and Multiple Dose, Step 3 | 0 |
2/Interval Doses (Multiple) Step 4 | 0 |
Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO
Participants in Arm 1 and 2 were analyzed in Step 2 for an in vivo increase in resting CD4+ T cell- associated HIV RNA (RCVL) after administration of a single dose of VOR 400 mg PO (NCT01319383)
Timeframe: Arm1: Baseline, Visit 5 and Arm 2: Baseline and Visit 3
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Step 2, Visit 5 | 8 |
2/Interval Dosing, Visit 3 | 4 |
Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Each of Two Multiple Dose Cycles (11 Doses/Cycle)
Participants in Arm 1, Step 3 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after 11 doses of VOR 400 mg PO. This cycle was repeated after a 5 - 8 week rest period for a 2nd series and measurement. (NCT01319383)
Timeframe: Baseline, Visit 18, Visit 29
Intervention | Participants (Count of Participants) |
---|---|
Arm 1 - Single and Multiple Dose, Step 3 | 0 |
Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Multiple (n = 10) Interval Doses
Participants in Arm 2, Step 4 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after administration of 10 doses of VOR 400 mg PO, given 72 hours apart. (NCT01319383)
Timeframe: Baseline, Visit 9
Intervention | Participants (Count of Participants) |
---|---|
Interval Doses (Multiple) Step 4 | 3 |
Number of Participants With a Significant in Vivo Response in Resting Cell Infection (RCI) and HIV RNA After Paired Doses
Induction of significant in vivo RCI and RCLV response after 2 doses of VOR 400 mg PO administered 48 hours apart or 72 hours apart (NCT01319383)
Timeframe: Baseline, Visit 6
Intervention | Participants (Count of Participants) |
---|---|
Interval Dosing , Step 3 (48 hr Interval) | 0 |
Interval Dosing, Step 3 (72 Hour Interval) | 6 |
Number of Participants With Confirmed Hematologic Toxicity >/= Grade 2 and Related to VOR Per Division of AIDS (DAIDS) Grading Table
DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Steps 2 and 3 | 0 |
2/Interval Dosing, Steps 2, 3 and 4 | 0 |
Number of Participants With Confirmed Non-hematologic Toxicity >/= Grade 3 and Related to VOR Per Division of AIDS (DAIDS) Grading Table
DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Steps 2 and 3 | 0 |
2/Interval Dosing, Steps 2, 3 and 4 | 0 |
Number of Participants With Measurable Changes in Plasma HIV-1 RNA
Assess for detectible HIV-1 RNA > 150 copies/mL, confirmed by repeat evaluation, following VOR dose. By standard assay and single copy assay. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 1 week after last VOR dose
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Steps 2 and 3 | 0 |
2/Interval Dosing, Steps 2, 3 and 4 | 0 |
Histone H4 Acetylation
Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks
Intervention | Fold increase pre to post vorinostat (Mean) |
---|---|
Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.19 |
Quantitative Viral Outgrowth
Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16
Intervention | Participants with undetectable outgrowth (Number) |
---|---|
Control (Arm A - ART Only) | 12 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 6 |
Total HIV DNA From CD4 T-cells
The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18
Intervention | HIV-DNA copies/mill CD4+ T cells (log10) (Mean) |
---|---|
Control (Arm A - ART Only) | 2.95 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.06 |
Viral Inhibition
"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks
Intervention | Percentage elimination (Mean) |
---|---|
Control (Arm A - ART Only) | -18.25 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 1.50 |
CD8+ T-cell Responses
Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
Intervention | % cells CD8+ CD107a+ IFNγ+ (Median) | |
---|---|---|
Post randomisation week 9 | Post randomisation week 12 | |
Control (Arm A - ART Only) | 0.052 | 0.062 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.194 | 0.263 |
Percentage of CD4+ CD154+ IFNγ+ T Cells
Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
Intervention | % cells CD4+ CD154+ IFNγ+ (Median) | |
---|---|---|
Post randomisation week 9 | Post randomisation week 12 | |
Control (Arm A - ART Only) | 0.006 | 0.006 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.097 | 0.109 |
Trials
2 trials available for vorinostat and Viremia
Article | Year |
---|---|
Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; DNA; Estrogen Receptor alpha; Female | 2022 |
Broad activation of latent HIV-1 in vivo.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Administration Schedule; HIV In | 2016 |
Other Studies
4 other studies available for vorinostat and Viremia
Article | Year |
---|---|
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
Topics: Broadly Neutralizing Antibodies; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Viremia; | 2022 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques.
Topics: Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Darunavir; DNA, Viral; Drug Therapy, Co | 2014 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |